Chemo and Immunotherapy with Different Radiation Types for Breast Cancer
Part of Cancer clinical trials.
This trial tests giving chemotherapy, an immunotherapy drug (PD-1 inhibitor), and different types of radiation before surgery for people with a common type of breast cancer (HR+/HER2-). The goal is to see which radiation plan works best to shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HR-positive and HER2-negative (a specific subtype).
- Your tumor must be at least 1-2 cm and may have spread to nearby lymph nodes, but not to distant organs.
- You must be well enough to perform daily activities (ECOG score 0 or 1).
- Your heart, liver, kidneys, and blood counts must be working well (specific lab tests are needed).
- You cannot have had another cancer in the last 5 years, except for some very low-risk types.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for a certain type of breast cancer (hormone receptor-positive, HER2-negative, with fast-growing cells). The goal is to see if this combination shrinks tumors more effectively before removal.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.